image
Healthcare - Medical - Instruments & Supplies - NYSE - US
$ 225.15
-0.889 %
$ 65.1 B
Market Cap
37.97
P/E
1. INTRINSIC VALUE

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.[ Read More ]

The intrinsic value of one BDX stock under the base case scenario is HIDDEN Compared to the current market price of 225 USD, Becton, Dickinson and Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BDX

image
FINANCIALS
20.2 B REVENUE
4.16%
2.42 B OPERATING INCOME
14.87%
1.73 B NET INCOME
12.81%
3.84 B OPERATING CASH FLOW
28.60%
-5.51 B INVESTING CASH FLOW
-670.11%
2.09 B FINANCING CASH FLOW
206.64%
5.44 B REVENUE
8.96%
650 M OPERATING INCOME
-9.09%
487 M NET INCOME
-9.31%
1.26 B OPERATING CASH FLOW
145.44%
-288 M INVESTING CASH FLOW
72.73%
1.12 B FINANCING CASH FLOW
-34.31%
Balance Sheet Decomposition Becton, Dickinson and Company
image
Current Assets 8.68 B
Cash & Short-Term Investments 1.42 B
Receivables 2.53 B
Other Current Assets 4.72 B
Non-Current Assets 44.1 B
Long-Term Investments 0
PP&E 7.07 B
Other Non-Current Assets 37 B
Current Liabilities 6.64 B
Accounts Payable 1.64 B
Short-Term Debt 1.14 B
Other Current Liabilities 3.86 B
Non-Current Liabilities 20.3 B
Long-Term Debt 15.2 B
Other Non-Current Liabilities 5.19 B
EFFICIENCY
Earnings Waterfall Becton, Dickinson and Company
image
Revenue 20.2 B
Cost Of Revenue 0
Gross Profit 20.2 B
Operating Expenses 6.05 B
Operating Income 2.42 B
Other Expenses 699 M
Net Income 1.73 B
RATIOS
100.00% GROSS MARGIN
100.00%
12.02% OPERATING MARGIN
12.02%
8.55% NET MARGIN
8.55%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Becton, Dickinson and Company
image
Net Income 1.73 B
Depreciation & Amortization 2.29 B
Capital Expenditures -725 M
Stock-Based Compensation 0
Change in Working Capital 0
Others -168 M
Free Cash Flow 3.12 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Becton, Dickinson and Company
image
Wall Street analysts predict an average 1-year price target for BDX of $286 , with forecasts ranging from a low of $270 to a high of $312 .
BDX Lowest Price Target Wall Street Target
270 USD 19.92%
BDX Average Price Target Wall Street Target
286 USD 26.92%
BDX Highest Price Target Wall Street Target
312 USD 38.57%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.04 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Becton, Dickinson and Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
71.8 K USD 1
6-9 MONTHS
2.03 M USD 3
9-12 MONTHS
802 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
5 months ago
Jun 10, 2024
Sell 71.8 K USD
Spoerel Thomas J
SVP,Controller&Chief Acct Off
- 300
239.31 USD
6 months ago
May 15, 2024
Sell 188 K USD
Goette Roland
EVP and President EMEA
- 800
235.29 USD
6 months ago
May 15, 2024
Sell 332 K USD
Goette Roland
EVP and President EMEA
- 1400
236.99 USD
6 months ago
May 15, 2024
Sell 261 K USD
Goette Roland
EVP and President EMEA
- 1100
237.46 USD
6 months ago
May 13, 2024
Sell 402 K USD
Goette Roland
EVP and President EMEA
- 1700
236.28 USD
6 months ago
May 13, 2024
Sell 373 K USD
Goette Roland
EVP and President EMEA
- 1572
237.14 USD
6 months ago
May 13, 2024
Sell 6.66 K USD
Goette Roland
EVP and President EMEA
- 28
237.9 USD
6 months ago
Apr 30, 2024
Sell 399 K USD
Garrison Michael David
EVP & President Medical
- 1715
232.81 USD
8 months ago
Mar 14, 2024
Sell 67.2 K USD
Spoerel Thomas J
SVP,Controller&Chief Acct Off
- 282
238.29 USD
11 months ago
Dec 11, 2023
Sell 288 K USD
Garrison Michael David
EVP & President Medical
- 1239
232.46 USD
11 months ago
Nov 28, 2023
Sell 514 K USD
Byrd Richard
EVP & President Interventional
- 2156
238.47 USD
1 year ago
Sep 05, 2023
Sell 126 K USD
Byrd Richard
EVP & President Interventional
- 459
274.48 USD
1 year ago
Aug 28, 2023
Sell 239 K USD
Fraser Claire
Director
- 848
281.66 USD
1 year ago
Aug 11, 2023
Sell 826 K USD
Hickey David
EVP & President, Life Sciences
- 2974
277.85 USD
1 year ago
Aug 08, 2023
Sell 360 K USD
Garrison Michael David
EVP & President Medical
- 1300
277.13 USD
1 year ago
Feb 03, 2023
Sell 353 K USD
Byrd Richard
EVP & President Interventional
- 1421
248.6 USD
2 years ago
Aug 15, 2022
Sell 126 K USD
Hickey David
EVP & President, Life Sciences
- 475
265 USD
2 years ago
Aug 15, 2022
Sell 2.52 M USD
Polen Thomas E Jr
Chairman, CEO and President
- 9500
265.13 USD
2 years ago
Aug 09, 2022
Sell 1.9 M USD
Khichi Samrat S.
EVP and General Counsel
- 7295
260.44 USD
2 years ago
Aug 09, 2022
Sell 430 K USD
Polen Thomas E Jr
Executive Vice President
- 1652
260 USD
2 years ago
Jun 07, 2022
Sell 115 K USD
Spoerel Thomas J
VP Controller & Chief Acct Off
- 443
260 USD
2 years ago
May 06, 2022
Sell 122 K USD
Hickey David
EVP & President, Life Sciences
- 475
256 USD
2 years ago
Feb 25, 2022
Sell 163 K USD
Larson Betty D
EVP HR & CHRO
- 601
271.9 USD
2 years ago
Feb 08, 2022
Sell 228 K USD
Fraser Claire
Director
- 841
271.7 USD
2 years ago
Feb 03, 2022
Sell 1.73 M USD
Conroy Alexandre
EVP of Integrated Supply Chain
- 6410
270.16 USD
2 years ago
Dec 16, 2021
Sell 141 K USD
Larson Betty D
EVP HR & CHRO
- 552
255 USD
2 years ago
Dec 16, 2021
Sell 711 K USD
Larson Betty D
EVP HR & CHRO
- 2789
255 USD
2 years ago
Dec 07, 2021
Sell 58.2 K USD
Spoerel Thomas J
VP Controller & Chief Acct Off
- 233
250 USD
3 years ago
Sep 08, 2021
Sell 69.4 K USD
Spoerel Thomas J
VP Controller & Chief Acct Off
- 267
260 USD
3 years ago
Sep 08, 2021
Sell 130 K USD
Hickey David
EVP & President, Life Sciences
- 500
260 USD
3 years ago
Sep 08, 2021
Sell 130 K USD
RIMEL REBECCA W
Director
- 500
260 USD
3 years ago
Sep 03, 2021
Sell 1.79 M USD
Lim James C
Executive Vice President
- 6956
257.44 USD
3 years ago
Sep 03, 2021
Sell 129 K USD
RIMEL REBECCA W
Director
- 500
257.1 USD
3 years ago
Sep 02, 2021
Sell 62 K USD
RIMEL REBECCA W
Director
- 244
254 USD
3 years ago
Aug 30, 2021
Sell 52.2 K USD
RIMEL REBECCA W
Director
- 207
252 USD
3 years ago
Aug 18, 2021
Sell 97.4 K USD
Fraser Claire
Director
- 387
251.58 USD
3 years ago
Aug 17, 2021
Sell 52.2 K USD
RIMEL REBECCA W
Director
- 207
252 USD
3 years ago
Aug 06, 2021
Sell 64.5 K USD
Spoerel Thomas J
VP Controller & Chief Acct Off
- 266
242.3 USD
3 years ago
May 28, 2021
Sell 829 K USD
Lim James C
Executive Vice President
- 3429
241.68 USD
3 years ago
May 27, 2021
Sell 94.1 K USD
Fraser Claire
Director
- 390
241.36 USD
3 years ago
Nov 23, 2020
Sell 214 K USD
Goette Roland
EVP and President, EMEA
- 930
230.1 USD
4 years ago
Jul 09, 2020
Sell 331 K USD
Kaltenbach Patrick
EVP & Pres Life Sciences
- 1272
260 USD
4 years ago
Jun 05, 2020
Sell 255 K USD
Kaltenbach Patrick
EVP & Pres Life Sciences
- 1049
243.2 USD
4 years ago
Jun 02, 2020
Sell 54.4 K USD
Kaltenbach Patrick
EVP & Pres Life Sciences
- 222
244.83 USD
4 years ago
May 08, 2020
Sell 198 K USD
Fraser Claire
Director
- 771
256.56 USD
4 years ago
Mar 16, 2020
Sell 976 K USD
Khichi Samrat S.
EVP and General Counsel
- 4349
224.53 USD
4 years ago
Feb 11, 2020
Sell 207 K USD
Fraser Claire
Director
- 800
258.73 USD
4 years ago
Feb 11, 2020
Sell 181 K USD
Fraser Claire
Director
- 700
258.7 USD
4 years ago
Feb 04, 2020
Sell 410 K USD
Campion Simon D
EVP and Segment President
- 1439
285.09 USD
4 years ago
Feb 04, 2020
Sell 408 K USD
Mas Ribo Alberto
EVP and Pres, Life Sciences
- 1430
285 USD
4 years ago
Jan 28, 2020
Sell 8.01 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 28514
280.96 USD
4 years ago
Jan 27, 2020
Sell 7.16 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 25546
280.09 USD
4 years ago
Jan 23, 2020
Sell 1.76 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 6284
280.06 USD
4 years ago
Jan 24, 2020
Sell 2.01 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 7177
280.13 USD
4 years ago
Jan 08, 2020
Sell 3.81 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 13860
275.19 USD
4 years ago
Jan 10, 2020
Sell 5.41 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 19675
275.15 USD
4 years ago
Jan 02, 2020
Sell 9.05 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 33365
271.28 USD
4 years ago
Dec 16, 2019
Sell 3.2 M USD
Mas Ribo Alberto
EVP and Pres, Life Sciences
- 11860
269.51 USD
4 years ago
Dec 16, 2019
Sell 1.2 M USD
Polen Thomas E Jr
Executive Vice President
- 4432
269.63 USD
4 years ago
Dec 12, 2019
Sell 89.2 K USD
Kaltenbach Patrick
EVP & Pres Life Sciences
- 339
263.23 USD
4 years ago
Dec 12, 2019
Sell 3.09 M USD
FORLENZA VINCENT A
Chairman, CEO and President
- 11626
265.57 USD
4 years ago
Dec 13, 2019
Sell 136 K USD
Spoerel Thomas J
VP Controller & Chief Acct Off
- 506
267.95 USD
4 years ago
Dec 06, 2019
Sell 81.6 K USD
Kaltenbach Patrick
EVP & Pres Life Sciences
- 312
261.51 USD
7. News
Becton, Dickinson and Company Q4: Shifting To High-Growth Areas Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care product group is expected to significantly boost BD's Advanced Patient Monitoring segment. BD plans to reduce debt leverage to 2.5x and repurchase $1 billion in shares, enhancing financial stability and shareholder value. seekingalpha.com - 4 days ago
Are Investors Undervaluing Becton, Dickinson and Company (BDX) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 5 days ago
Looking for a Growth Stock? 3 Reasons Why Becton Dickinson (BDX) is a Solid Choice Becton Dickinson (BDX) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 1 week ago
BDX or MMSI: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 week ago
Becton, Dickinson and Company (BDX) Q4 2024 Earnings Call Transcript Becton, Dickinson and Company (NYSE:BDX ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of Medical Segment Conference Call Participants Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Matt Miksic - Barclays Matt Taylor - Jefferies Rick Wise - Stifel Operator Hello and welcome to BD's Fourth Quarter and Full Year Fiscal 2024 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com, or by phone at 800-839-1337 for domestic calls and area code +1-402-220-0489 for international calls. seekingalpha.com - 1 week ago
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments. zacks.com - 1 week ago
Becton Dickinson (BDX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates Becton Dickinson (BDX) came out with quarterly earnings of $3.81 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $3.42 per share a year ago. zacks.com - 1 week ago
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices Becton Dickinson surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices. reuters.com - 1 week ago
BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic Q4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectively FY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organic FY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectively FY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively Company issues FY25 revenue guidance including GAAP growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5% Company issues FY25 adjusted diluted EPS guidance of $14.25 to $14.60 1, which reflects growth of about 10% at the midpoint FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended September 30, 2024. prnewswire.com - 1 week ago
BD Board Increases Dividend for 53rd Consecutive Year FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. prnewswire.com - 1 week ago
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings? Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues. zacks.com - 1 week ago
8. Profile Summary

Becton, Dickinson and Company BDX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 65.1 B
Dividend Yield 0.00%
Description Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Contact 1 Becton Drive, Franklin Lakes, NJ, 07417-1880 https://www.bd.com
IPO Date Feb. 21, 1973
Employees 70000
Officers Mr. Greg Rodetis Head of Investor Relations Ms. Michelle Quinn Executive Vice President & General Counsel Ms. Elizabeth McCombs Executive Vice President & Chief Technology Officer Claudia Curtis Senior Vice President, Chief Ethics & Compliance Officer Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. Senior Vice President, Chief Scientific Officer & Co-Chair of Scientific Advisory Board Ms. Denise Russell Fleming Executive Vice President of Technology & Global Services and Chief Information Officer Mr. Thomas E. Polen Jr. President, Chief Executive Officer & Chairman Ms. Shana Carol Neal Executive Vice President & Chief People Officer Mr. Michael Garrison Executive Vice President & President of Medical segment Mr. Thomas J. Spoerel Senior Vice President, Controller & Chief Accounting Officer